Health Insurance Fund press representative Sander Rajamäe told ERR it was too early to give comprehensive answers.
“We are currently awaiting marketing approval for molnupiravir – it could happen in the coming weeks. The European Commission is declaring a framework contract at around the same time. Estonia will participate in the tender once declared. The amounts of molnupiravir are rather modest because we are waiting for more effective drugs, ”said Rajamäe.
Once Merck Sharp & Dohme’s molnupiravir arrives in Estonia, it will be moved to the Health Board warehouse from where it will be transported to wholesalers and pharmacies.
The drug will be added to the list of discounted drugs once it has received marketing authorization and can be prescribed to patients in the coronavirus risk group by family physicians.
The patient will have to pay € 2.50 for the drug, ”Rajamäe said.
The European Medicines Agency could recommend the use of the drug against the coronavirus paxlovid before obtaining a marketing authorization.
“The manufacturer has not yet filed for a preliminary analysis or marketing authorization,” added Rajamäe.
Follow ERR News on Facebook and Twitter and never miss an update!